Nebivolol for treatment patients with arterial hypertension

Abstract

Beta-adrenergic blocking agent is included in the group of primary agentsfor treatment of patients with AH. In the pathogenesis of AH,one of the main causes leading to raisingthe blood pressure isendothelial dysfunction.Correction ofendothelial dysfunctionis AH treatment strategic aim.Nebivololis a cardioselectivethird-generationvasodilatingβ-adrenergic blocking agent, which is in addition toβ-adrenergic blocking effect, can alsoincrease endogenousproduction of NOin the endothelial cellsdue to the decreasing of oxidative degradation. As a result,nebivololprovides positivehemodynamic effects on patients with AH, decreasingperipheral resistanceandblood pressure.

Keywords

• arterial hypertension
• β-adrenergic blocking agent
• endothelial dysfunction
• nebivolol